← All trials
NCT06262594
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2024
- Primary completion
- Apr 18, 2025
- Completion date
- Apr 18, 2026
- First posted
- Feb 16, 2024
- Last posted
- May 8, 2024
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ManitobaLead sponsor
- Duke UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.